Search

This document is a correction notice for an article titled "Triply Enhanced Immunotherapy via Dual Glycan Reforming Integrated with Perforation" published in the journal Advanced Science. The correction addresses misuses of images in Figures 2, 4, and 5, as well as in the Supporting Information. The corrected figures are presented in the notice. The correction does not affect the results and conclusions of the published article. The article discusses the triple functions of SLO-Gal and SLO-NEU on 4T1 cells, the characterization and degradation of TEID, and the triply enhanced immunotherapy with TEID on tumor-bearing mice. [Extracted from the article]

The enhancement of immunotherapy is an emerging direction to develop highly effective and practical cancer therapeutic methods. Here a triply enhanced immunotherapy drug (TEID) is designed for ingeniously integrating in situ dual glycan reforming with perforation on cell membrane. The TEID is composed of galactose and neuraminidase conjugated streptolysin O (SLO‐Gal and SLO‐NEU), which are encapsulated in a hyaluronic acid (HA) shell for targeted recognition to tumor tissue via cell surface CD44. After targeted delivery and HAase‐mediated degradation in the tumor region, the TEID releases SLO‐Gal and SLO‐NEU, which can easily anchor Gal and NEU on the tumor cell membrane via the perforation of SLO to perform dual glycan reforming for the introduction of Gal and the cleavage of sialic acid. The former can activate immune cells to secret cytokines for immune‐killing, and the latter can weaken the immune inhibition to improve the immunotherapeutic efficacy. Meanwhile, the perforation of SLO can promote the delivery of cytokines into the tumor cells to further enhance the efficacy. The designed triply enhanced immunotherapy strategy opens a significant and promising route to promote clinical immunotherapy of cancer. [ABSTRACT FROM AUTHOR]